



*JFW*  
PATENT  
Case Docket No. *B5-W2*  
Date: *7/8/04*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : TAN  
App. No. : 10/821,679  
Filed : APRIL 8, 2004  
For : Annatto Extract Compositions,  
Including Geranyl Geraniols And  
Methods Of Use  
Examiner : UNKNOWN  
Group Art Unit : UNKNOWN

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 8, 2004

(Date)

*JFW*  
Agent of Record, Reg. No. 51,763

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

The PTO did not receive the following  
listed item(s) *Reference #23*

Dear Sir:

Enclosed for filing in the above-identified application are:

- ☒ An Information Disclosure Statement.
- ☒ A PTO Form 1449 with 69 enclosed references.
- ☒ A PTO Form 2038 is attached to charge to the credit card account \$0.00 to cover the above fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to the credit card account
- ☒ Return prepaid postcard.

Respectfully submitted

By: *JFW*

Registration No. 51,763  
Agent of Record  
Customer No.038051

**INFORMATION DISCLOSURE STATEMENT**

Applicant : TAN  
App. No. : 10/821,679  
Filed : APRIL 8, 2004  
For : Annatto Extract Compositions, Including  
Geranyl Geraniols And Methods Of Use  
Examiner : UNKNOWN  
Group Art Unit : UNKNOWN


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Enclose is form PTO-1449 listing eighty (80) references. Copies of disclosed U.S. patents and/or publications are not included pursuant to PTO waiver of the requirement under 37 C.F.R. §1.98(a)(2)(i) for applications filed after June 30, 2003. Copies of other references, if listed, are enclosed. Documents Nos. 12 through 80 have been disclosed in the present patent application.

This Information Disclosure Statement is being filed with an RCE or within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Dated: July 8, 2004

Respectfully submitted,  
By: 

Registration No. 51,763  
Agent of Record  
Customer No.038051



FORM PTO-449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BT-002	APPLICATION NO. 10/821,679
	APPLICANT Tan, Barrie et al.	
	FILING DATE April 8, 2004	GROUP Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	2003139467	July 24, 2003	Igarashi			
	2	6441029	August 27, 2002	Elson			
	3	6358997	March 19, 2002	Clark			
	4	6350453	February 26, 2002	Tan			
	5	6083979	July 4, 2000	Sehti			
	6	5756109	May 26, 1998	Burger			
	7	5660691	August 26, 1997	Barnicki			
	8	5602184	February 11, 1997	Myers			
	9	5318993	June 7, 1994	Pearce			
	10	5217992	June 8, 1993	Wright			
	11	5157132	October 20, 1992	Tan			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	12	Adachi, J. and G. Ioannidis (2000). "Glucocorticoid-induced osteoporosis." Drug Development Research 49: 120-134.
	13	Amin, D., R. Rutledge, et al. (1997). "RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase." J Pharmacol Exp Ther. 281(2): 746-752.
	14	Ayanian, J., C. Fuchs, et al. (1988). "Lovastatin and rhabdomyolysis." Ann Intern Med. 109: 682-683.
	15	Baker, S. and M. Tarnopolsky (2001). "Statin myopathies: pathophysiologic and clinical perspectives." Clin Invest Med. 24(5): 258-272.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BT-002	APPLICATION NO. 10/821,679
	APPLICANT Tan, Barrie et al.	
	FILING DATE April 8, 2004	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	16	Ballantyne, C., A. Corsini, et al. (2003). "Risk for myopathy with statin therapy in high-risk patients." Arch. Intern. Med. 163(5): 553-564.
	17	Bentinger, M., J. Grunler, et al. (1998). "Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase." Arch Biochem Biophys 353(2): 191-198.
	18	Bliznakov, E. (2002). "Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case--a modern Pandora's box." Biomed Pharmacother. 56(1): 56-59.
	19	Cenedella, R. (1995). "Role of transcription, translation, and protein turnover in controlling the distribution of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the lens." Invest Ophthalmol Vis Sci. 36(10): 2133-2141.
	20	Cenedella, R. (1997). "Posttranscriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in lens epithelial cells by mevalonate-derived nonsterols." Exp Eye Res. 65(1): 63-72.
	21	Chamberlain, L. (2001). "Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes." FEBS Letters 507(3): 357-361.
	22	Ciosek, C., D. Magnin, et al. (1993). "Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo." J. Biol. Chem 268: 24832-24837.
	23	Colli, S., S. Eligini, et al. (1997). "Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis." Arterioscler Thromb Vasc Biol 17: 265-272.
	24	Craveiro, A. A., et al., (1989). "The Presence of Geranylgeraniol in Bixa Orelana Linn.," Quimica Nova, 12(3):297-298.
	25	Cruz, A. and B. Gruber (2002). "Statins and osteoporosis: Can these lipid-lowering drugs also bolster bones?" Cleveland Clinic Journal of Medicine 69(4): 277-288.
	26	Danesi, R., C. McLellan, et al. (1995). "Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation." Biochem Biophys Res Commun. 206(2): 637-643.
	27	DeFronzo, R. A. (1998). "Pathogenesis of Type 2 Diabetes: Metabolic & Molecular Implications for Identifying Diabetes Genes." Ann. Rev. Diabetes: 1-93.
	28	Flint, O., B. Masters, et al. (1997). "HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture." Toxicol Appl Pharmacol. 145(1): 99-110.
	29	Flint, O., B. Masters, et al. (1997). "Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro." Toxicol Appl Pharmacol 145(1): 91-98.
	30	Folkers, K., A. Osterborg, et al. (1997). "Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer." Biochem Biophys Res Commun. 234(2): 296-299.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BT-002	APPLICATION NO. 10/821,679
	APPLICANT Tan, Barrie et al.	
	FILING DATE April 8, 2004	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	31	Gavish, D., E. Leibovitz, et al. (2000). "Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety." J. Intern. med. 247: 563-569.
	32	Grünler, J., J. Ericsson, et al. (1994). "Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins." Biochim Biophys Acta. 1212(3): 259-77.
	33	Guillet-Deniau, I., et al. (2003). "Glucose induces de novo fatty acid synthesis in rat skeletal muscle through a SREBP-1c dependent pathway." Diabetes 52(Suppl. 1): extended abstract. 1024P.
	34	Hamilton-Craig, I. (2001). "Statin-associated myopathy." Med J Aust. 175(9): 486-489.
	35	Haslinger, B., M. Goedde, et al. (2002). "Simvastatin Increases Fibrinolytic Activity in Human Peritoneal Mesothelial Cells Independent of Cholesterol Lowering." Kidney International 62(5): 1611-1619.
	36	Hevener, A., W. He, et al. (2003). "Muscle-specific Pparg deletion causes insulin resistance." Nat Med. 9(12): 1491-1497.
	37	Holdaas, H., A. Jardine, et al. (2001). "Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial." Kidney Int. 60(5): 1990-1997.
	38	Johnston, S. and L. Kelland (2001). "Farnesyl transferase inhibitors--a novel therapy for breast cancer." Endocr Relat Cancer. 8(3): 227-235.
	39	Jondiko, I. J. O. and Pattenden, G., (1989). "Terpenoids and an Apocarotenoid from Seeds of Bixa Orellana," Phytochemistry, 28(11):3159-3162.
	40	Judy, W., T. Nguyen, et al. (2004). "Evidence for regression of PSA and tumor size in patients with prostate cancer." Submitted for publication in Proc. Natl. Acad. Sci.
	41	Kraegen, E. (1998). "Physiologic manifestations of PPAR-gamma activation: preclinical studies." Clinical Courier 16(48): 5-7.
	42	Lankin, V., A. Tikhaze, et al. (2000). "Intensification in vivo of free radical oxidation of low density lipoproteins in plasma from patients with myocardial ischemia treated by HMG-CoA-reductase pravastatin and suppression of lipid peroxidation by ubiquinone Q10." Biull Eksp Biol Med. 129(2): 176-179.
	43	Lehmann, J., L. Moore, et al. (1995). "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)." J Biol Chem. 270(22): 12953-12956.
	44	Luckman, S., F. Coxon, et al. (1998). "Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages." J Bone Miner Res. 13(11): 1668-1678.
	45	McCarty, M. (1999). "Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics?" Med Hypotheses. 52(2): 397-400.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BT-002	APPLICATION NO. 10/821,679
	APPLICANT Tan, Barrie et al.	
	FILING DATE April 8, 2004	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	46	McGuire, T. and S. Sebti (1997). "Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity." <i>Oncogene</i> 14: 305-312.
	47	McLaughlin, e. a. (2003). "Prediction of IR with plasma TG or TG/HDL ratio." <i>Diabetes</i> 52(Suppl. 1): A224 extended abstract. 962P.
	48	Miller, P. (2001). "Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis." <i>Osteoporos Int. Suppl</i> 3: S3-S10.
	49	Miquel, K., A. Pradines, et al. (1998). "Competitive Inhibition of Choline Phosphotransferase by Geranylgeraniol and Farnesol Inhibits Phosphatidylcholine Synthesis and Induces Apoptosis in Human Lung Adenocarcinoma A549 Cells." <i>J. of Biol. Chem.</i> 273(40): 26179-26186.
	50	Olbricht, C., C. Wanner, et al. (1997). "Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses." <i>Clin Pharmacol Ther.</i> 62(3): 311-321.
	51	Omar, M., J. Wilson, et al. (2001). "Rhabdomyolysis and HMG-CoA reductase inhibitors." <i>The Annals of Pharmacotherapy</i> 35(9): 1096-1107.
	52	Ownby, S. and R. Hohl (2002). "Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells." <i>Lipids</i> 37(2): 185-92.
	53	Pearce, B., R. Parker, et al. (1992). "Hypocholesterolemic activity of synthetic and natural tocotrienols." <i>J Med Chem.</i> 35(20): 3595-3606.
	54	Peters, J., N. Hennuyer, et al. (1997). "Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice." <i>J Biol Chem.</i> 272(43): 27307-27312.
	55	Poels, P. and F. Gabreels (1993). "Rhabdomyolysis: a review of the literature." <i>Clin. Neurol. Neurosurg.</i> 95: 175-192.
	56	Polverino, A. and S. Patterson (1997). "Selective activation of caspases during apoptotic induction in HL-60 cells. Effects Of a tetrapeptide inhibitor." <i>J Biol Chem.</i> 272(11): 7013-7021.
	57	Qureshi, et al., (1995). "Response of Hypercholesterolemic Subjects to Administration of Tocotrienols," <i>Lipids</i> , 30(12).
	58	Raner, G., A. Muir, et al. (2002). "Farnesol as an inhibitor and substrate for rabbit liver microsomal P450 enzymes." <i>Biochem Biophys Res Commun.</i> 293(1): 1-6.
	59	Regazzi, M., I. Iacona, et al. (1993). "Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients." <i>Transplant Proc.</i> 25: 2732-2734.
	60	Rogers, M. (2000). "Statins: lower lipids and better bones?" <i>Nature Medicine</i> 6(1): 21-23.
	61	Saito, J., J. Davis, et al. (1995). "Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study." <i>Calcif Tissue Int.</i> 57(2): 115-119.
	62	Schlienger, R., W. Haefeli, et al. (2001). "Risk of cataract in patients treated with statins." <i>Arch Intern Med.</i> 161(16): 2021-2026.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BT-002	APPLICATION NO. 10/821,679
	APPLICANT Tan, Barrie et al.	
	FILING DATE April 8, 2004	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	63	Smith, P., R. Eydeloth, et al. (1991). "HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies." J Pharmacol Exp Ther. 257(3): 1225-1235.
	64	Smith, S. (1998). "The molecular pharmacology of PPAR-gamma." Clinical Courier 16(48): 3-4.
	65	Spach, D., J. Bauwens, et al. (1991). "Rhabdomyolysis associated with lovastatin and erythromycin use." West J. Med. 154: 213-215.
	66	Staels, B., J. Dallongeville, et al. (1998). "Mechanism of action of fibrates on lipid and lipoprotein metabolism." Circulation 98(19): 2088-2093.
	67	Stark, W., M. Blaskovich, et al. (1998). "Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells." Am J Physiol. 275: L55-L63.
	68	Takahashi, N., T. Kawada, et al. (2002). "Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes." FEBS Lett. 514(2-3): 315-322.
	69	Talley, N., A. Weaver, et al. (1992). "Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorder." Am J Epidemiol. 136(2): 165-177.
	70	Thai, L., J. S. Rush, et al. (1999). "Farnesol is utilized for isoprenoid biosynthesis in plant cells via farnesyl pyrophosphate formed by successive monophosphorylation reactions." Proc Natl Acad Sci 96(23): 13080-13085.
	71	Thibault, A., D. Samid, et al. (1996). "Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer." Clin Cancer Res. 2(3): 484-491.
	72	Theriault, A., et al., (1999). "Tocotrienol: A Review of Its Therapeutic Potential," Clinical Biochemistry, 32(5):309-319.
	73	VERIS (1989). The role of Vitamin E in exercise, Vitamin E Research & Information Service (November).
	74	VERIS (1990). Protective role of vitamin E in cataract development, Vitamin E Research & Information Service (February).
	75	Watkins, T. R. and Bierenbaum, M. L., (1999). "Tocotrienols: Biological and Health Effects," in Antioxidant Status, Diet, Nutrition, and Health, Andreas M. Papas, ed. (CRC Press) pp. 479-496.
	76	Watts, G., C. Castelluccio, et al. (1993). "Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin." J Clin Pathol. 46(11): 1055-1057.
	77	Watts, N., D. Freedholm, et al. (1999). "The clinical tolerability profile of alendronate." Int J Clin Pract Suppl. 101: 51-61.
	78	Willson, T., M. Lambert, et al. (2001). "Peroxisome proliferator-activated receptor gamma and metabolic disease." Annu Rev Biochem. 70: 341-367.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BT-002	APPLICATION NO. 10/821,679
	APPLICANT Tan, Barrie et al.	
	FILING DATE April 8, 2004	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
79	Wong, W., J. Dimitroulakos, et al. (2002). "HMG-CoA Reductase Inhibitors and the Malignant Cell: the Statin Family of Drugs as Triggers of Tumor-Specific Apoptosis." Leukemia 16: 508-519.	
80	Yu, W., et al., (1999). "Induction of Apoptosis in Human Breast Cancer Cells by Tocopherols and Tocotrienols," Nutrition and Cancer, 33(1):26-32.	

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	